Mass spectrometry for congenital disorders of glycosylation, CDG
In: Journal of chromatography. B 838(1):3-8; Jg. 838 (2006) 1, S. 3-8
Konferenz
- print, 46 ref
Zugriff:
Congenital disorders of glycosylation (CDG) constitute a group of diseases affecting N-linked glycosylation pathways. The classical type of CDG, now called CDG-I, results from deficiencies in the early glycosylation pathway for biosynthesis of lipid-linked oligosaccharide and its transfer to proteins in endoplasmic reticulum, while the CDG-II diseases are caused by defects in the subsequent processing steps. Mass spectrometry (MS) produced a milestone in CDG research, by localizing the CDG-I defect to the early glycosylation pathway in 1992. Currently, MS of transferrin, either by electrospray ionization or matrix-assisted laser desorption/ionization, plays the central role in laboratory screening of CDG-I. On the other hand, the glycopeptide analysis recently developed for site-specific glycans of glycoproteins allows detailed glycan analysis in a high throughput manner and will solve problems in CDG-II diagnosis. These techniques will facilitate studying CDG, a field now expanding to O-linked glycosylation and to acquired as well as inherited conditions that can affect protein glycosylation.
Titel: |
Mass spectrometry for congenital disorders of glycosylation, CDG
|
---|---|
Autor/in / Beteiligte Person: | WADA, Yoshinao |
Link: | |
Quelle: | Journal of chromatography. B 838(1):3-8; Jg. 838 (2006) 1, S. 3-8 |
Veröffentlichung: | Amsterdam: Elsevier Science, 2006 |
Medientyp: | Konferenz |
Umfang: | print, 46 ref |
ISSN: | 1570-0232 (print) |
Schlagwort: |
|
Sonstiges: |
|